- Home
- APP vs BMY Comparison
APP vs BMY Comparison
Compare APP & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APP | BMY |
|---|---|---|
| Founded | 2012 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.7B | 113.5B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | APP | BMY |
|---|---|---|
| Price | $346.80 | $64.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $694.44 | $61.73 |
| AVG Volume (30 Days) | 6.5M | ★ 12.4M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | ★ 115.23 | N/A |
| EPS | ★ 7.32 | N/A |
| Revenue | ★ $5,480,717,000.00 | N/A |
| Revenue This Year | $47.88 | N/A |
| Revenue Next Year | $29.14 | N/A |
| P/E Ratio | $45.86 | ★ $17.26 |
| Revenue Growth | ★ 16.38 | N/A |
| 52 Week Low | $332.19 | $42.52 |
| 52 Week High | $745.61 | $68.10 |
Technical Indicators
Market Signals| Indicator | APP | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 29.19 | 61.95 |
| Support Level | N/A | $53.81 |
| Resistance Level | $482.50 | N/A |
| Average True Range (ATR) | 18.77 | 1.86 |
| MACD | -2.26 | 0.14 |
| Stochastic Oscillator | 3.29 | 52.41 |
Price Performance
Historical ComparisonAbout APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.